Golimumab

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1711 publications

Pulmonary rheumatoid nodules in a patient treated with golimumab.

Pulmonary rheumatoid nodules in a patient treated with golimumab.

Journal: ARP rheumatology

Published: April 12, 2026

Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study.

Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study.

Journal: The Journal of rheumatology

Published: April 01, 2026

Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study.

Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study.

Journal: The Journal of rheumatology

Published: April 01, 2026

Considerations for infection risks identified in target safety review.

Considerations for infection risks identified in target safety review.

Journal: The Journal of toxicological sciences

Published: April 01, 2026

A 70-Year-Old Woman Receiving Immunosuppressive Therapy Presenting With Iliopsoas Abscess, Pulmonary Miliary Tuberculosis, and Secondary Hemophagocytic Lymphohistiocytosis.

A 70-Year-Old Woman Receiving Immunosuppressive Therapy Presenting With Iliopsoas Abscess, Pulmonary Miliary Tuberculosis, and Secondary Hemophagocytic Lymphohistiocytosis.

Journal: The American journal of case reports

Published: February 25, 2026

Comparative cost-utility analysis of ixekizumab, tofacitinib, and golimumab in psoriatic arthritis: a real-world Markov model simulation.

Comparative cost-utility analysis of ixekizumab, tofacitinib, and golimumab in psoriatic arthritis: a real-world Markov model simulation.

Journal: Expert review of pharmacoeconomics & outcomes research

Published: February 09, 2026

Five-Year Drug Survival and Discontinuation Reasons for Eight Biological Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis: A Retrospective Analysis of 1182 Patients from the Niigata Orthopedic Surgery Rheumatoid Arthritis Database (NOSRAD).

Five-Year Drug Survival and Discontinuation Reasons for Eight Biological Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis: A Retrospective Analysis of 1182 Patients from the Niigata Orthopedic Surgery Rheumatoid Arthritis Database (NOSRAD).

Journal: Journal of clinical medicine

Published: February 08, 2026

Clinical Features and Outcome of Patients With Juvenile Spondyloarthropathy in a Tertiary Hospital in the Philippines.

Clinical Features and Outcome of Patients With Juvenile Spondyloarthropathy in a Tertiary Hospital in the Philippines.

Journal: Clinical pediatrics

Published: February 05, 2026

Successful Reintroduction of Golimumab in a Patient With Rheumatoid Arthritis and Prolonged Epstein-Barr Virus Reactivation With Persistent Anti-Viral Capsid Antigen IgM Antibodies: A Case Report.

Successful Reintroduction of Golimumab in a Patient With Rheumatoid Arthritis and Prolonged Epstein-Barr Virus Reactivation With Persistent Anti-Viral Capsid Antigen IgM Antibodies: A Case Report.

Journal: Cureus

Published: January 03, 2026

Biosimilars in Adult and Pediatric Noninfectious Uveitis.

Biosimilars in Adult and Pediatric Noninfectious Uveitis.

Journal: Clinical ophthalmology (Auckland, N.Z.)

Published: December 29, 2025

Tumor Necrosis Factor-Alpha (TNF-α) Inhibitor Treatment in Hidradenitis Suppurativa: A Population-Based Retrospective Cohort Study of Comorbid Risks.

Tumor Necrosis Factor-Alpha (TNF-α) Inhibitor Treatment in Hidradenitis Suppurativa: A Population-Based Retrospective Cohort Study of Comorbid Risks.

Journal: Cureus

Published: December 26, 2025

Predicting self-administered biologic nonadherence in Medicare fee-for-service beneficiaries with inflammatory bowel disease using machine learning models.

Predicting self-administered biologic nonadherence in Medicare fee-for-service beneficiaries with inflammatory bowel disease using machine learning models.

Journal: Journal of managed care & specialty pharmacy

Published: December 24, 2025

Showing 1-12 of 1,711

Last Updated: 04/28/2026